{
  "ticker": "CMP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968945",
  "id": "02968945",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0932",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrx63l14q6jy.pdf",
  "summary": "- **Record sales orders**: $63.4M (+22% YoY), led by Sleep & Neurology (+39% to $53.0M) and SaaS (+49% to $6.7M).  \n- **US growth**: Sales orders +115% YoY; Somfit SaaS orders +675% to $3.1M.  \n- **Revenue (unaudited)**: $51.0M (+4% YoY), with SaaS revenue +41% to $6.0M. No MEG revenue in FY25.  \n- **Profitability**: EBITDA ~$3M (subject to audit). Margin improvement from SaaS scaling and cost control.  \n- **Capital raise**: $4.1M for working capital.  \n- **FY26 guidance**: Revenue \u2265$70M, EBITDA ~$9M. SaaS expected to contribute >20% of revenue.  \n- **Growth drivers**: US Somfit D launch ($150M\u2013$300M market opportunity), 3 MEG systems ($15M revenue expected in FY26).  \n\n*No material timetable or capital structure changes identified.*",
  "usage": {
    "prompt_tokens": 1888,
    "completion_tokens": 230,
    "total_tokens": 2118,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T23:52:28.283715"
}